Adewole S Adamson

List of Publications by Year
in descending order

58 papers	1,319 citations	516561 16 h-index	377752 34 g-index
58 all docs	58 docs citations	58 times ranked	1904 citing authors

#	Article	IF	Citations
1	Representation and misdiagnosis of dark skin in a large-scale visual diagnostic challenge. Journal of the American Academy of Dermatology, 2022, 86, 950-951.	0.6	12
2	Estimating Overdiagnosis of Melanoma Using Trends Among Black and White Patients in the US. JAMA Dermatology, 2022, 158, 426.	2.0	22
3	UV Exposure and the Risk of Keratinocyte Carcinoma in Skin of Color. JAMA Dermatology, 2022, 158, 542.	2.0	8
4	Billing Patterns and Geographic Distribution of Dermatologist-Dermatopathologists in the US From 2013 to 2017. JAMA Dermatology, 2022, 158, 581.	2.0	1
5	Differentiating Between Lead-Time Bias and True Survival Benefits When Discussing Racial and Ethnic Disparities in Melanomaâ€”Reply. JAMA Dermatology, 2022, , .	2.0	0
6	Risk of nonâ€acral cutaneous melanoma after the diagnosis of acral melanoma. British Journal of Dermatology, 2022, , .	1.4	0
7	Decision Curve Analysis and the Net Benefit of Novel Tests. JAMA Dermatology, 2022, 158, 684.	2.0	2
8	Should Recommendations for Cancer Screening Differentiate on Race?. , 2022, 1, .		3
9	Association of Tumor Characteristics With Insurance Type Among Patients Undergoing Mohs Micrographic Surgery for Nonmelanoma Skin Cancer. JAMA Dermatology, 2022, 158, 919.	2.0	4
10	An Antiracist Framework for Racial and Ethnic Health Disparities Research. , 2022, , 156-158.		0
11	Association of surgical interval and survival among hospital and non-hospital based patients with melanoma in North Carolina. Archives of Dermatological Research, 2021, 313, 653-661.	1.1	4
12	Reconsidering Named Honorifics in Medicineâ€the Troubling Legacy of Dermatologist Albert Kligman. JAMA Dermatology, 2021, 157, 153.	2.0	8
13	The Rapid Rise in Cutaneous Melanoma Diagnoses. New England Journal of Medicine, 2021, 384, 72-79.	13.9	224
14	Toward automated assessment of mole similarity on dermoscopic images. Journal of Medical Imaging, 2021, 8, 014506.	0.8	1
15	Changes in Use of Radiotherapy Among Dermatologists From 2013 to 2017. JAMA Dermatology, 2021, 157, 322.	2.0	0
16	Reframing racial and ethnic disparities in atopic dermatitis in Black and Latinx populations. Journal of Allergy and Clinical Immunology, 2021, 148, 1104-1111.	1.5	40
17	Melanoma and Racial Health Disparities in Black Individualsâ€Facts, Fallacies, and Fixes. JAMA Dermatology, 2021, 157, 1031.	2.0	15
18	UV Exposure and the Risk of Cutaneous Melanoma in Skin of Color. JAMA Dermatology, 2021, 157, 213.	2.0	61

#	Article	IF	Citations
19	Pediatric-Onset Refractory Lupus Erythematosus Panniculitis Treated With Rituximab. , 2021, 108, E44-E46.		3
20	Screening for Melanoma in Men: a Cost-Effectiveness Analysis. Journal of General Internal Medicine, 2020, 35, 1175-1181.	1.3	10
21	Evaluation of the Merits and Limitations of Evidence-Based Medicineâ€"Reply. JAMA Dermatology, 2020, 156, 925.	2.0	0
22	Systemic Absorption of Sunscreen. JAMA - Journal of the American Medical Association, 2020, 323, 223.	3.8	19
23	Gene Expression Profile Testing for Thin Melanoma. JAMA Dermatology, 2020, 156, 837.	2.0	9
24	Twitter Journal Clubs. JAMA Dermatology, 2020, 156, 729.	2.0	23
25	Active Comparator Trial Designs Used to Promote Development of Innovative New Medications. , 2020, 106, E4-E6.		2
26	An Antiracist Framework for Racial and Ethnic Health Disparities Research. Pediatrics, 2020, 146, .	1.0	17
27	Concordance between dermatologist self-reported and industry-reported interactions at a national dermatology conference. Cutis, 2020, 105, 203-208;E1.	0.4	0
28	Eliminating Copayments for Skin Cancer Screeningâ€"A Public Health Policy With Insufficient Evidence. JAMA Dermatology, 2019, 155, 1339.	2.0	7
29	Review and Update on Evidence-Based Surgical Treatment Recommendations for Nonmelanoma Skin Cancer. Dermatologic Clinics, 2019, 37, 425-433.	1.0	16
30	A State-of-the-Art Review Highlighting Medical Overuse in Dermatology, 2017-2018. JAMA Dermatology, 2019, 155, 1410.	2.0	14
31	Commentary: Position statement on augmented intelligence (AuI). Journal of the American Academy of Dermatology, 2019, 81, 998-1000.	0.6	27
32	Time's up to adopt a biopsychosocial model to address racial and ethnic disparities in asthma outcomes. Journal of Allergy and Clinical Immunology, 2019, 143, 2024-2025.	1.5	25
33	Machine Learning and the Cancer-Diagnosis Problem â€" No Gold Standard. New England Journal of Medicine, 2019, 381, 2285-2287.	13.9	69
34	Impact of Industry Payments on Prescribing Patterns for Tumor Necrosis Factor Inhibitors Among Medicare Beneficiaries. Journal of General Internal Medicine, 2019, 34, 176-178.	1.3	8
35	Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment. Journal of the American Academy of Dermatology, 2019, 80, 577-578.	0.6	7
36	Surgical re-excision vs. observation for histologically dysplastic naevi: a systematic review of associated clinical outcomes. British Journal of Dermatology, 2018, 179, 590-598.	1.4	7

#	Article	IF	Citations
37	Trends in Medicare spending on topical immunomodulators and chemotherapies. Journal of the American Academy of Dermatology, 2018, 78, 173-175.	0.6	9
38	Medicare Part D payments for brand and generic drugs prescribed by dermatologists. Journal of the American Academy of Dermatology, 2018, 79, 575-577.	0.6	4
39	Geographic Distribution of Nonphysician Clinicians Who Independently Billed Medicare for Common Dermatologic Services in 2014. JAMA Dermatology, 2018, 154, 30.	2.0	27
40	Prescription-level factors associated with primary nonadherence to dermatologic medications. Journal of Dermatological Treatment, 2018, 29, 300-304.	1.1	4
41	Treatment of Non-melanoma Skin Cancer in the Elderly. Current Geriatrics Reports, 2018, 7, 216-221.	1.1	0
42	Observation of Moderately Dysplastic Nevi With Positive Margins. JAMA Dermatology, 2018, 154, 1387.	2.0	4
43	Translating Administrative Health Care Data to Treatment Decisions in Dermatology. JAMA Dermatology, 2018, 154, 1256.	2.0	1
44	Machine Learning and Health Care Disparities in Dermatology. JAMA Dermatology, 2018, 154, 1247.	2.0	281
45	Distance to pharmacy and risk of medication primary nonadherence. Dermatology Online Journal, 2018, 24, .	0.2	1
46	A Missed Opportunity to Discuss Racial and Gender Bias in Dermatology. JAMA Dermatology, 2017, 153, 110.	2.0	1
47	Mohs Micrographic Surgery Use in the United States Based on Medicare Dataâ€"Reply. JAMA Dermatology, 2017, 153, 835.	2.0	0
48	Medicare Part D Payments for Topical Steroids. JAMA Dermatology, 2017, 153, 755.	2.0	24
49	Patient-provider race and sex concordance and the risk for medication primary nonadherence. Journal of the American Academy of Dermatology, 2017, 76, 1193-1195.	0.6	19
50	Should we refer to skin as â€œethnic?â€• Journal of the American Academy of Dermatology, 2017, 76, 1224-1225.	0.6	8
51	Characteristics of Medicare Payments to Dermatologists in 2013. JAMA Dermatology, 2017, 153, 95.	2.0	12
52	Association Between Method of Prescribing and Primary Nonadherence to Dermatologic Medication in an Urban Hospital Population. JAMA Dermatology, 2017, 153, 49.	2.0	14
53	Association of Delays in Surgery for Melanoma With Insurance Type. JAMA Dermatology, 2017, 153, 1106.	2.0	58
54	Perineal Rash and Perianal Pain. Journal of Emergency Medicine, 2015, 49, e59-e60.	0.3	0

#	Article	IF	Citations
55	Tissue Inhibitor of Metalloproteinase 1 Is Preferentially Expressed in Th1 and Th17 T-Helper Cell Subsets and Is a Direct Stat Target Gene. PLoS ONE, 2013, 8, e59367.	1.1	15
56	The Current STATus of lymphocyte signaling: new roles for old players. Current Opinion in Immunology, 2009, 21, 161-166.	2.4	101
57	Signal transduction and Th17 cell differentiation. Microbes and Infection, 2009, 11, 599-611.	1.0	52
58	Morphological and functional platelet abnormalities in Berkeley sickle cell mice. Blood Cells, Molecules, and Diseases, 2008, 41, 109-118.	0.6	16